Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALK1 | P51570 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10355841 | 0.80 | HSD17B3 (0.46) | GALK1MEN1KMT2APAK1THRA | |
| SCHEMBL10355838 | 0.78 | THRB (0.48) | THRATHRBHSD17B3 | |
| SCHEMBL10605850 | 0.76 | THRA (0.57) | MEN1KMT2APAK1ALDH1A1GAA | |
| SCHEMBL7834034 | 0.76 | MEN1 (0.56) | MEN1KMT2APAK1KDM4EALDH1A1 | |
| SCHEMBL1457795 | 0.76 | TPMT (0.67) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL2797148 | 0.76 | ALDH1A1 (0.49) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL10323753 | 0.76 | ALDH1A1 (0.49) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL10355978 | 0.76 | ESR1 (0.57) | MEN1KMT2APAK1ALDH1A1THRA | |
| SCHEMBL24722331 | 0.75 | MEN1 (0.55) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL6624909 | 0.75 | PDE4B (0.55) | MEN1KMT2AKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257264-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7087599-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050137192-A1 | Estrogen receptor modulators | PARKER DANN R JR (US) | 2005-06-23 | — | — | US | disclosed |
| US-20030027840-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027840-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | GALK1 2684/4885MEN1 3259/4885KMT2A 1157/4885 |
| US-20050137192-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | GALK1 2684/4885MEN1 3259/4885KMT2A 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.